Diaphragmatic Effects of Combined Infraclavicular Brachial Plexus Block and Suprascapular Nerve Block (ICB-SNB)
Evaluation of the Effects of Combined Infraclavicular Brachial Plexus Block and Suprascapular Nerve Block on the Diaphragm in Arthroscopic Shoulder Surgery
研究概览
地位
详细说明
This prospective observational study was conducted to evaluate the effects of combined infraclavicular brachial plexus block and anterior suprascapular nerve block on diaphragmatic excursion in patients undergoing elective arthroscopic shoulder surgery.
Patients scheduled for arthroscopic shoulder surgery under regional anesthesia were enrolled in the study. Prior to block administration, baseline diaphragmatic excursion was assessed using ultrasonography during both normal and deep breathing. Each measurement was repeated three times, and the mean value was recorded. The same measurements were repeated 30 minutes after completion of the block procedures using an identical protocol.
The percentage change in diaphragmatic excursion between baseline and post-block measurements was calculated for both normal and deep breathing. Hemidiaphragmatic paralysis was categorized according to the degree of reduction in diaphragmatic excursion as absent (≤25% reduction), partial (25.1-74.9% reduction), or complete (≥75% reduction).
All nerve blocks were performed under ultrasound guidance by anesthesiologists experienced in regional anesthesia techniques. The infraclavicular brachial plexus block was performed using 15 mL of 0.5% bupivacaine deposited around the posterior cord and 8 mL of 0.5% bupivacaine around the lateral cord. The anterior suprascapular nerve block was performed with 7 mL of 0.5% bupivacaine. In addition, arthroscopic portal sites were infiltrated with 10 mL of 0.2% bupivacaine to provide supplementary analgesia.
All patients received intravenous midazolam (2 mg) and paracetamol (1 g) during the intraoperative period. Additional analgesic or sedative medication was administered when required according to clinical conditions and surgical needs. Block performance time, requirement for supplemental analgesia or sedation, and any block-related adverse events were recorded.
The primary outcome measure was the change in diaphragmatic excursion measured by ultrasonography 30 minutes after block administration. Secondary outcome measures included the incidence and severity of hemidiaphragmatic paralysis, block performance time, duration of postoperative analgesia, need for additional intraoperative analgesia or sedation, time to first analgesic requirement, patient and surgeon satisfaction, block-related complications, and conversion to general anesthesia.
The study was designed to investigate whether the combination of infraclavicular brachial plexus block and anterior suprascapular nerve block could provide effective anesthesia and analgesia for arthroscopic shoulder surgery while minimizing impairment of diaphragmatic function and reducing the incidence of clinically significant hemidiaphragmatic paralysis.
研究类型
注册 (实际的)
联系人和位置
学习地点
-
-
Ankara
-
Ankara、Ankara、土耳其(türkiye)、06500
- Gazi University Faculty of Medicine Hospital
-
-
参与标准
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
取样方法
研究人群
描述
Inclusion Criteria:
- Patients aged 18-80 years.
- ASA physical status I-III.
- Scheduled for elective arthroscopic shoulder surgery.
- Ability to provide written informed consent
Exclusion Criteria:
- Refusal to undergo peripheral nerve block.
- Pre-existing peripheral neuropathy.
- Known pulmonary, hepatic, or renal disease.
- Allergy to local anesthetics.
- Infection at the block site.
- Pre-existing neurological deficit.
- Body mass index (BMI) > 40 kg/m².
- Coagulopathy.
- Sepsis.
Previous surgery at the planned block site.
- Major psychiatric disorders.
- Inability to complete diaphragmatic ultrasonographic assessment.
学习计划
研究是如何设计的?
设计细节
队列和干预
团体/队列 |
|---|
|
Patients Undergoing Arthroscopic Shoulder Surgery
Patients undergoing arthroscopic shoulder surgery who received a combined infraclavicular brachial plexus block and anterior suprascapular nerve block.
Diaphragmatic excursion was evaluated using ultrasonography before and after block administration.
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change in Diaphragmatic Excursion at 30 Minutes After Block Administration
大体时间:30 minutes after block administration
|
Diaphragmatic excursion measured by ultrasonography during normal and deep breathing before block administration and 30 minutes after block administration.
The percentage change from baseline was calculated.
|
30 minutes after block administration
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Incidence of Hemidiaphragmatic Paralysis
大体时间:30 minutes after block administration
|
Presence of hemidiaphragmatic paralysis determined by ultrasonographic assessment of diaphragmatic excursion.
|
30 minutes after block administration
|
|
Degree of Hemidiaphragmatic Paralysis
大体时间:30 minutes after block administration
|
Hemidiaphragmatic paralysis classified as absent (≤25% reduction), partial (25.1-74.9%
reduction), or complete (≥75% reduction)
|
30 minutes after block administration
|
|
Block Performance Time
大体时间:From needle insertion to completion of the block procedure
|
Time required to complete the combined infraclavicular brachial plexus block and anterior suprascapular nerve block.
|
From needle insertion to completion of the block procedure
|
|
Additional Intraoperative Analgesia Requirement
大体时间:From surgical incision to the end of surgery
|
Requirement for supplemental analgesic medication during surgery.
|
From surgical incision to the end of surgery
|
|
Time to First Analgesic Requirement
大体时间:Up to 24 hours after surgery
|
Time from completion of the block procedure to the first postoperative analgesic request.
|
Up to 24 hours after surgery
|
|
Block-Related Complications
大体时间:From block administration until 24 hours after surgery
|
Incidence of block-related adverse events including Horner syndrome, hoarseness, nausea/vomiting, and hemodynamic complications.
|
From block administration until 24 hours after surgery
|
合作者和调查者
调查人员
- 首席研究员:IRFAN GUNGOR, MD、Gazi University Faculty of Medicine
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- 2024-GUTF-028
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.